How to buy Idera Pharmaceuticals stock - 10 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Idera Pharmaceuticals stock

Own Idera Pharmaceuticals stock in just a few minutes.

Idera Pharmaceuticals, Inc is a biotechnology business based in the US. Idera Pharmaceuticals shares (IDRA) are listed on the NASDAQ and all prices are listed in US Dollars. Idera Pharmaceuticals employs 32 staff and has a market cap (total outstanding shares value) of USD$57 million.

How to buy shares in Idera Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Idera Pharmaceuticals. Find the stock by name or ticker symbol: IDRA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Idera Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Idera Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Idera Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Idera Pharmaceuticals share price

Use our graph to track the performance of IDRA stocks over time.

Idera Pharmaceuticals shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$1.22 - USD$6.14
50-day moving average USD$3.5049
200-day moving average USD$3.7143
Wall St. target priceUSD$1.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.661

Buy Idera Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Idera Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Idera Pharmaceuticals financials

Gross profit TTM USD$-16,707,000
Return on assets TTM -51.02%
Return on equity TTM -2280.6%
Profit margin 0%
Book value $1.304
Market capitalisation USD$57 million

TTM: trailing 12 months

Shorting Idera Pharmaceuticals shares

There are currently 2.2 million Idera Pharmaceuticals shares held short by investors – that's known as Idera Pharmaceuticals's "short interest". This figure is 169.4% up from 806,620 last month.

There are a few different ways that this level of interest in shorting Idera Pharmaceuticals shares can be evaluated.

Idera Pharmaceuticals's "short interest ratio" (SIR)

Idera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Idera Pharmaceuticals shares currently shorted divided by the average quantity of Idera Pharmaceuticals shares traded daily (recently around 778794.98207885). Idera Pharmaceuticals's SIR currently stands at 2.79. In other words for every 100,000 Idera Pharmaceuticals shares traded daily on the market, roughly 2790 shares are currently held short.

However Idera Pharmaceuticals's short interest can also be evaluated against the total number of Idera Pharmaceuticals shares, or, against the total number of tradable Idera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Idera Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Idera Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0636% of the tradable shares (for every 100,000 tradable Idera Pharmaceuticals shares, roughly 64 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Idera Pharmaceuticals.

Find out more about how you can short Idera Pharmaceuticals stock.

Idera Pharmaceuticals share dividends

We're not expecting Idera Pharmaceuticals to pay a dividend over the next 12 months.

Have Idera Pharmaceuticals's shares ever split?

Idera Pharmaceuticals's shares were split on a 1:8 basis on 29 July 2018. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Idera Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Idera Pharmaceuticals shares which in turn could have impacted Idera Pharmaceuticals's share price.

Idera Pharmaceuticals share price volatility

Over the last 12 months, Idera Pharmaceuticals's shares have ranged in value from as little as $1.22 up to $6.14. A popular way to gauge a stock's volatility is its "beta".

IDRA.US volatility(beta: 1.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Idera Pharmaceuticals's is 1.8897. This would suggest that Idera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Idera Pharmaceuticals overview

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site